adjuvant therapy for breast cancer
February 13, 2026
Source: drugdu
39
On February 12, Daiichi Sankyo announced that its injectable detrastuzumab (Uroder®, DS-8201a, T-DXd) has been approved for inclusion in the Breakthrough Therapy Designation (BTD) program by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of adult patients with HER2-positive breast cancer who still have residual invasive lesions after neoadjuvant anti-HER2 therapy. Detrastuzumab was developed by Daiichi Sankyo and co-developed by Daiichi Sankyo and AstraZeneca.A jointly developed HER2-targeting antibody-drug conjugate (ADC).
https://finance.eastmoney.com/a/202602123648930874.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- Rising Star in Oral Weight Loss! Hengrui’s GLP 1R/GIPR Agonist Succeeds in Phase II Study February 13, 2026
- The approval of telpopril monotherapy for type 2 diabetes has driven an upgrade in the management paradigm February 13, 2026
- Oral insulin launch fails; China Resources Pharmaceutical plans to sell Tianmai Biotechnology February 13, 2026
- Hanyu Pharmaceutical’s glatiramer acetate injection receives FDA approval in the United States. February 13, 2026
- Global ADC market size $16.5 billion February 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
